Two Sigma Securities’s Soleno Therapeutics SLNO Stock Holding History

Two Sigma Securities’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,278	Closed	-$377K	–	2026
2025 Q1	$377K	Buy	+5,278	New	+$257K	0.06%	473
2023 Q1	–	Sell	-19,932	Closed	-$39.5K	–	3215
2022 Q4	$39.5K	Buy	+19,932	New	+$24.8K	﹤0.01%	2195
2022 Q3	–	Sell	-848	Closed	-$2K	–	3044
2022 Q2	$2K	Buy	+848	New	+$2.35K	﹤0.01%	2138
2022 Q1	–	Sell	-4,488	Closed	-$28K	–	2470
2021 Q4	$28K	Buy	+4,488	New	+$47.1K	﹤0.01%	1372
2021 Q3	–	Sell	-1,281	Closed	-$22K	–	1911
2021 Q2	$22K	Buy	+1,281	New	+$21.6K	﹤0.01%	1447
2018 Q1	–	Sell	-1,432	Closed	-$39K	–	2930
2017 Q4	$39K	Buy	1,432 +842	+143%	+$24.3K	﹤0.01%	1562
2017 Q3	$23K	Buy	+590	New	+$23.3K	﹤0.01%	818
2017 Q1	–	Sell	-203	Closed	-$12K	–	1098
2016 Q4	$12K	Buy	+203	New	+$14.1K	﹤0.01%	670

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Two Sigma Securities's SLNO Position: Q2 2025 in Review

Two Sigma Securities sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 5,278 shares — an estimated $377K sold.

Two Sigma Securities first reported a position in SLNO in Q4 2016 and held it in 8 quarters. The position peaked at $377K in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

Two Sigma Securities reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
Two Sigma Securities sold 5,278 Soleno Therapeutics shares in Q2 2025, an estimated $377K.
Two Sigma Securities first reported a position in Soleno Therapeutics in Q4 2016 and held it in 8 quarters.
Two Sigma Securities's Soleno Therapeutics position peaked at $377K in Q1 2025.
233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.